Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,011 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
[Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study].
Szucs TD, Guggenberger G, Berger K, März W, Schäfer JR. Szucs TD, et al. Among authors: berger k. Herz. 1998 Aug;23(5):319-29. doi: 10.1007/BF03044365. Herz. 1998. PMID: 9757381 Clinical Trial. German.
[Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients].
Berger K, Klose G, Szucs TD. Berger K, et al. Med Klin (Munich). 1997 Jun 15;92(6):363-9. doi: 10.1007/BF03044779. Med Klin (Munich). 1997. PMID: 9297070 Review. German.
[Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
Szucs TD, Berger K, März W, Schäfer JR. Szucs TD, et al. Among authors: berger k. Herz. 2000 Aug;25(5):487-94. doi: 10.1007/pl00001961. Herz. 2000. PMID: 10992997 German.
[Economic evaluation of various hepatitis B vaccination strategies in children and adolescents].
Szucs TD, Smala A, Berger K, Windorfer A. Szucs TD, et al. Among authors: berger k. Med Klin (Munich). 1998 Aug 15;93(8):468-77. doi: 10.1007/BF03042596. Med Klin (Munich). 1998. PMID: 9747102 German.
Cost of illness and its predictors for Parkinson's disease in Germany.
Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R. Spottke AE, et al. Among authors: berger k. Pharmacoeconomics. 2005;23(8):817-36. doi: 10.2165/00019053-200523080-00007. Pharmacoeconomics. 2005. PMID: 16097843
Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany.
Berger K, Ehlken B, Kugland B, Augustin M. Berger K, et al. J Dtsch Dermatol Ges. 2005 Jul;3(7):511-8. doi: 10.1111/j.1610-0387.2005.05729.x. J Dtsch Dermatol Ges. 2005. PMID: 15967010
[Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study].
Szucs TD, Schwenkglenks M, Berger K, Karsch K. Szucs TD, et al. Among authors: berger k. Z Kardiol. 2003 Mar;92(3):236-44. doi: 10.1007/s00392-003-0908-5. Z Kardiol. 2003. PMID: 12658471 Clinical Trial. German.
Burden of pulmonary arterial hypertension in Germany.
Wilkens H, Grimminger F, Hoeper M, Stähler G, Ehlken B, Plesnila-Frank C, Berger K, Resch A, Ghofrani A. Wilkens H, et al. Among authors: berger k. Respir Med. 2010 Jun;104(6):902-10. doi: 10.1016/j.rmed.2010.01.002. Epub 2010 Feb 9. Respir Med. 2010. PMID: 20149617
[Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
Szucs TD, Goedde M, Berger K, Kiowski W. Szucs TD, et al. Among authors: berger k. Schweiz Med Wochenschr. 1997 Jul 22;127(29-30):1234-41. Schweiz Med Wochenschr. 1997. PMID: 9333933 Clinical Trial. German.
Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective.
Berger K, Fischer T, Szucs TD. Berger K, et al. Eur J Cancer. 1998 Nov;34(12):1894-901. doi: 10.1016/s0959-8049(98)00260-3. Eur J Cancer. 1998. PMID: 10023312
1,011 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page